Literature DB >> 2218502

Impact of mass treatment of onchocerciasis with ivermectin on the transmission of infection.

H R Taylor1, M Pacqué, B Muñoz, B M Greene.   

Abstract

Onchocerciasis is a major blinding disease that, until recently, has been essentially untreatable. Ivermectin is a safe and effective drug for the mass treatment of onchocerciasis and when used on an individual basis, it reduces the ability of the treated person to transmit Onchocerca volvulus infection. In the present study, the effect of community-based ivermectin treatment on the degree of transmission within the community was assessed by determining the incidence of new infection in children. Ivermectin was distributed annually on three occasions to the eligible members of a population of approximately 14,000 people living on a rubber plantation in a forest area endemic for onchocerciasis. After 2 years, the prevalence of infection in 5-year-old children decreased by 21%. The annual incidence in an uninfected cohort of children decreased by 35% and, after age-specific adjustment, the reduction in incidence in 7- to 12-year-old children was 45%. Thus, community-based distribution of ivermectin led to a significant reduction in incidence of new infection. These findings suggest that ivermectin can be important in reducing the transmission of onchocerciasis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2218502     DOI: 10.1126/science.2218502

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  21 in total

1.  Modeling targeted ivermectin treatment for controlling river blindness.

Authors:  Eric M Poolman; Alison P Galvani
Journal:  Am J Trop Med Hyg       Date:  2006-11       Impact factor: 2.345

2.  Transmission of Onchocerca volvulus continues in Nyagak-Bondo focus of northwestern Uganda after 18 years of a single dose of annual treatment with ivermectin.

Authors:  Moses N Katabarwa; Tom Lakwo; Peace Habomugisha; Stella Agunyo; Edson Byamukama; David Oguttu; Ephraim Tukesiga; Dickson Unoba; Patrick Dramuke; Ambrose Onapa; Edridah M Tukahebwa; Dennis Lwamafa; Frank Walsh; Thomas R Unnasch
Journal:  Am J Trop Med Hyg       Date:  2013-05-20       Impact factor: 2.345

Review 3.  Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis.

Authors:  K L Goa; D McTavish; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

4.  Immunoaffinity purification of avermectin-binding proteins from the free-living nematode Caenorhabditis elegans and the fruitfly Drosophila melanogaster.

Authors:  S P Rohrer; E B Jacobson; E C Hayes; E T Birzin; J M Schaeffer
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

Review 5.  Ivermectin for onchocercal eye disease (river blindness).

Authors:  Henry O D Ejere; Ellen Schwartz; Richard Wormald; Jennifer R Evans
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

6.  Ivermectin-dependent release of IL-1beta in response to ATP by peritoneal macrophages from P2X(7)-KO mice.

Authors:  Michèle Seil; Malika El Ouaaliti; Unai Fontanils; Irantzu Gorrono Etxebarria; Stéphanie Pochet; Giulia Dal Moro; Aida Marino; Jean-Paul Dehaye
Journal:  Purinergic Signal       Date:  2010-11-20       Impact factor: 3.765

7.  Molecular cloning and characterization of recombinant parasite antigens for immunodiagnosis of onchocerciasis.

Authors:  R Chandrashekar; K Masood; R M Alvarez; A F Ogunrinade; R Lujan; F O Richards; G J Weil
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

8.  Factors associated with compliance with community directed treatment with ivermectin for onchocerciasis control in Southwestern Ethiopia.

Authors:  Daniel Yirga; Kebede Deribe; Kifle Woldemichael; Mekite Wondafrash; Wondosen Kassahun
Journal:  Parasit Vectors       Date:  2010-06-02       Impact factor: 3.876

9.  Photoaffinity labeling of avermectin binding sites from Caenorhabditis elegans and Drosophila melanogaster.

Authors:  S P Rohrer; P T Meinke; E C Hayes; H Mrozik; J M Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

10.  Fifteen years of annual mass treatment of onchocerciasis with ivermectin have not interrupted transmission in the west region of cameroon.

Authors:  Moses N Katabarwa; Albert Eyamba; Philippe Nwane; Peter Enyong; Joseph Kamgno; Thomas Kueté; Souleymanou Yaya; Rosalie Aboutou; Léonard Mukenge; Claude Kafando; Coulibaly Siaka; Salifou Mkpouwoueiko; Demanga Ngangue; Benjamin Didier Biholong; Gervais Ondobo Andze
Journal:  J Parasitol Res       Date:  2013-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.